Merus BV Cash Flow Conversion Efficiency
Merus BV cash flow conversion efficiency. Based on the latest financial reports, Merus BV (MRUS) has a cash flow conversion efficiency ratio of -0.128x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-84.92 Million) by net assets ($661.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Merus BV (2013–2024)
Cash flow conversion efficiency of Merus BV from 2013 to 2024. This chart illustrates how Merus BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Merus BV for real-time trading data and today's change.
Merus BV Cash Flow Conversion Ratio Explained
Merus BV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Merus BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merus BV ranked by their cash flow conversion efficiency. Also see Merus BV (MRUS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huadong Medicine Co Ltd
SHE:000963
|
0.006x |
|
Stora Enso Oyj R
HE:STERV
|
0.003x |
|
Yealink Network Technology Corp Ltd
SHE:300628
|
0.059x |
|
Huali Industrial Group Company Limited
SHE:300979
|
0.144x |
|
FormFactor Inc
NASDAQ:FORM
|
0.056x |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
0.117x |
|
Leader Harmonious Drive Systems Co Ltd
SHG:688017
|
0.021x |
|
Apar Industries Limited
NSE:APARINDS
|
0.031x |
Annual Cash Flow Conversion Efficiency for Merus BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of Merus BV from 2013 to 2024. Review free cash flow generation of Merus BV to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $650.36 Million | $-185.84 Million | -0.286x | +28.40% |
| 2023-12-31 | $356.34 Million | $-142.21 Million | -0.399x | +34.23% |
| 2022-12-31 | $247.06 Million | $-149.90 Million | -0.607x | -221.76% |
| 2021-12-31 | $316.20 Million | $-59.63 Million | -0.189x | +75.87% |
| 2020-12-31 | $102.26 Million | $-79.90 Million | -0.781x | -62.71% |
| 2019-12-31 | $131.30 Million | $-63.05 Million | -0.480x | -8.93% |
| 2018-12-31 | $105.09 Million | $-46.33 Million | -0.441x | +43.58% |
| 2017-12-31 | $57.45 Million | $-44.88 Million | -0.781x | -3.32% |
| 2016-12-31 | $35.79 Million | $-27.06 Million | -0.756x | +7.08% |
| 2015-12-31 | $30.94 Million | $-25.18 Million | -0.814x | -119.85% |
| 2014-12-31 | $-4.33 Million | $-17.74 Million | 4.099x | +551.01% |
| 2013-12-31 | $10.58 Million | $-9.62 Million | -0.909x | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more